An In-depth Update on the Management of Acute Lymphoblastic Leukemia

Acute lymphoblastic leukemia, 3D illustration showing abundant lymphoblasts in blood

Program Overview This CME/CNE program will provide a comprehensive update of best practices for treating and managing patients with acute lymphoblastic leukemia (ALL). The expert faculty will outline molecular mutations and patient prognosis, including the t-acute lymphoblastic leukemia and the b-acute lymphoblastic leukemia subtypes. Current clinical trial data will be analyzed, particularly recent breakthroughs in […]

Continue reading


Scientific Updates for Optimal Outcomes in Patients with Bladder Cancer

Micrograph of Invasive urothelial carcinoma high grade. Invasive urothelial carcinoma is a type of Transitional cell carcinoma (TCC, also urothelial cell carcinoma or UCC) and is a type of cancer that develops in the urinary system: the kidney, urinary bladder, and accessory organs. It is the most common type of bladder cancer and cancer of the ureter, urethra, and urachus. Invasive urothelial carcinoma originates from tissue lining the inner surface of these hollow organs - transitional epithelium. It can extend from the kidney collecting system to the bladder. H&E Stain

Program Overview This CME/CNE activity will review recent advances in patients with Bladder Cancer as presented at the American Society of Clinical Oncology- Genitourinary Cancers (ASCO GU) 2019 Symposium in San Francisco, CA. Dr. Richard Lee will inform on clinical decision making for patients with bladder cancer by reviewing the science and tumor microenvironment. He will also […]

Continue reading


Best Practices for the Management of Non-Small Cell Lung Cancer

Micrograh of small cell carcinoma or also know as small cell lung cancer or oat-call carcinoma is a type of highly malignant cancer. PAP Stain

Program Overview This CME/CNE activity will review recent advances in patients with non-small cell lung cancer (NSCLC) incorporating data presented at the European Society For Medical Oncology (ESMO) 2018 Conference in Munich, Germany. The three expert faculty will analyze clinical trial data on the current science and emerging best practices for the treatment of NSCLC. The […]

Continue reading


The Increasing Role of Biosimilars in Oncology

3d render of immune system T cells attacking cancer cells (CAR T-cell therapy)

Program Overview This continuing education activity will focus on recent clinical trial data as well as therapeutic advances in the increasing role of biosimilars in oncology. The three expert faculty will review the fundamentals of biosimilars in oncology, including bioequivalence, totality of evidence, and interchangeability. A review of current clinical trial data of biosimilars for […]

Continue reading